The world’s oldest man, Yasutaro Koide recently died at the age of 112. Commentators as usual, focused on his reported “secret to longevity”: not smoking, drinking or overdoing it. No surprises there. But speculation on the basis of one individual is not necessarily the most helpful way of addressing this human quest for the Philosopher’s Stone.
The “very old” do spark our interest – but is our search for a secret to longevity actually misguided? Wouldn’t you rather live healthier than live longer in poor health? Surely, what we really want to know is how do we live well in old age.
Clearly as scientists we try to illuminate these questions using populations of people not just odd individuals. Many previous attempts have approached this question by looking for differences between young and old people, but this approach is often biased by the many social and cultural developments that happen between generations, including diet changes. Time itself should not be the focus – at least, in part, because time is one thing we are unlikely to be able to stop.
The real question behind our interest in people who survive into old age is how some manage to stay robust and fit while others become debilitated and dependent. To this end, recent scientific interest has turned to investigating the predictors of frailty within populations of roughly the same age. Frailty is a measure of how physically and mentally healthy an individual is. Studies show frailer older adults have an increased levels of low grade inflammation – so-called “inflammaging”.
New research published in Genome Medicine by Matt Jackson, from our group at King’s College London, investigated this question in an unlikely place – poo. Recent evidence indicates that our immune and inflammatory systems are trained and educated in our gut, through key interactions with gut bacteria. So we asked if changes in our gut bacteria could be part of the process of inflammation driving frailty.
Our recent work found that the frailer an individual, the lower the diversity of gut bacteria they have. We looked at stool samples from more than 700 healthy British twins and found that a group of bacteria belonging to the species with a tricky and slightly unpleasant name, Faecalibacterium prausnitzii, were found in higher amounts in the healthier twins. This is a particularly interesting microbe as it has been linked with good health in many other diseases such as inflammatory bowel disease and is believed to reduce inflammation of the gut. Could this bug help protect against frailty?

Putting in the research. Paper by Shutterstock
There were other microbes seen in increased amounts within the frailer twins. One was Eubacterium dolichum, which has been seen to increase in unhealthy Western diets. We found the same picture when comparing frailer, more elderly, individuals from the ELDERMET study, by the University of Cork. This suggests that dietary changes might be an easy way to encourage healthy ageing.
Our study does not yet clarify whether the changes to the gut bacteria are a cause of poor ageing itself or are just a consequence of frailty – longitudinal studies that follow people over several years will be needed to sort this out. But these results are exciting for researchers in the ageing field and suggest that if you want to age well you should perhaps do fewer crosswords and spend more time looking after your microbial garden, for example by eating plenty of plant fibre, for example in a Mediterranean-type diet.
Claire Steves receives funding from the MRC and the CDRF.
Tim Spector receives funding from the MRC and is director of the British Gut crowd funded project and author of The Diet Myth: the real science behind what we eat by W&N 2015
Tim Spector, Professor of Genetic Epidemiology, King's College London
This article was originally published on The Conversation. Read the original article.



Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 



